Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab for Untreated Indolent B-cell Lymphoma
NCT01239394Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2010
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma, sponsored by Massachusetts General Hospital. Started Dec 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)small lymphocytic lymphoma (SLL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT01239394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239394.